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Abstract
Plasmodium falciparum malariaisamajorglobalhealthproblem,causingapproximately780,000deathseachyear.Inresponse
to the spreading of P. falciparum drug resistance, WHO recommended in 2001 to use artemisinin derivatives in combination
with a partner drug (called ACT) as first-line treatment for uncomplicated falciparum malaria, and most malaria-endemic
countries have since changed their treatment policies accordingly. Currently, ACT are often the last treatments that can
effectively and rapidly cure P. falciparum infections permitting to significantly decrease the mortality and the morbidity due to
malaria. However, alarming signs of emerging resistance to artemisinin derivatives along the Thai-Cambodian border are of
major concern. Through long-term in vivo pressures, we have been able to select a murine malaria model resistant to
artemisinins. We demonstrated that the resistance of Plasmodium to artemisinin-based compounds depends on alterations of
heme metabolism and on a loss of hemozoin formation linked to the down-expression of the recently identified Heme
Detoxification Protein (HDP). These artemisinins resistant strains could be able to detoxify the free heme by an alternative
catabolism pathway involving glutathione (GSH)-mediation. Finally, we confirmed that artemisinins act also like quinolines
against Plasmodium via hemozoin production inhibition. The work proposed here described the mechanism of action of this
class of molecules and the resistance to artemisinins of this model. These results shouldhelp bothto reinforce the artemisinins
activity and avoid emergence and spread of endoperoxides resistance by focusing in adequate drug partners design. Such
considerations appear crucial in the current context of early artemisinin resistance in Asia.
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Introduction
Malaria is still the parasitic disease with the highest impact on
public health in endemic areas with 781.000 deaths recorded in
2009 [1]. Even though the price of efficient medications and the
lack of correct healthcare infrastructures are partially responsible
for this alarming situation, the spread of drug-resistance parasites
remains the major problem. While ACT (Artemisinin-based
Combination Therapies) are now widely used and are often the
only one recommended treatments against all Plasmodium falciparum
strains, early-resistance foci in South-East Asia have appeared
recently [2] and pose a threat to these current therapies.
To act against multi-drug resistant parasites, a detailed under-
standing of the mode action of the drugs is urgently needed. The
rodent malaria models enabled the selection of parasites that are
resistant to different antimalarial drugs, including recent molecules.
In this context, a long-term drug pressure was carried out on P. yoelii
nigeriensis in parallel with two main molecules: chloroquine (CQ) and
artemisinin (ART). The goal of this project was to set up a malaria
parasites model, in order to provide informations about the
mechanism of action of artemisinin and its derivatives [3].
Results and Discussion
Drug pressures conferred multi-resistance to
lysosomotropes (i.e. drugs targeting the parasite food
vacuole)
The selection of drug resistant lines was carried out over 5 years
by submitting in parallel the parasite strain P. yoelii nigeriensis to
progressively increased doses of ART and CQ (Figure 1). After 3-
year of drug pressure, the Fink’s test [4] was used to evaluate the
response of these selected parasite lines to the different drugs used
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32620for the selection pressures. Experiments were carried out on one
strain of each line randomly chosen (Y-ART3 and Y-CQ2) and on
the Y-control line (data not shown). Mice infected with any of the
selected resistant lines could not be cured by treatments with ART
(120 mg/kg sub-cutaneous (s.c.) whereas parasites of the Y-control
line remained sensitive to these drug regimen since no parasite
could be detected up to 30-days in the mice infected by this strain.
High doses of CQ did not cure mice infected by selected resistant
lines as well. On the other hand, 2 out of 3 of the mice infected
with the Y-control line and treated with CQ (185 mg/kg s.c.) were
cured. Even if a unique dose of CQ (185 mg/kg by s.c. injection)
did not totally cure the mice infected by the Y-control line, CQ
treatment was much more effective against the Y-control parasite
growth than it was against the selected lines. The Fink’s test was
therefore not adapted to study CQ resistance as the maximal dose
of CQ was too close to the dose that killed 50% of the mice
(LD50=195 mg/kg s.c).
However, we can see here that whatever the drug initially used
for selection (CQ or ART), all the resulting lines tested were
resistant (or less sensitive) to these two molecules indicating a
multi-drug resistance phenotype.
To quantify resistance acquisition ex vivo short-term cultures of
P. yoelii were therefore performed. This assay was done on the
resistant-selected lines and on the Y-control line (Tables 1, 2). The
results showed that there was a considerable decrease in the
susceptibility of all these selected lines, to quinolines (chloroquine,
mefloquine and quinine) and to endoperoxides (artemisinin,
artesunate, artemether, and artemisone [5]). As previously
observed with the Fink’s test, a phenotype of multi-drug resistance
was obtained after resistance selection done with CQ, or ART.
Whatever the molecules used for selection, each line exhibited a
phenotype with a high resistance index (RI: corresponds for a
given drug to the ratio of the IC50 value of the resistant line over
the IC50 value of the control line) for quinolines with values,
according to the strains tested, ranging from 67 to 152-fold for
chloroquine, 68 to 120-fold for mefloquine and 17 to 39-fold for
quinine (Table 1). Resistance to endoperoxides was also observed
as well (Table 2), ranging according to the strains tested from 3 to
264-fold for artemisinin, 6 to 87-fold for artesunate, 14 to 53-fold
for artemether and 13 to 21-fold for artemisone. However, this
phenomenon was not observed with all drugs since the resistance
index of sulfadoxine+pyrimethamine (SP) and atovaquone were
closer to the control lines (Table 3) with RI ranged from 0.7 to 1-
fold for SP and 0.3 to 2.2-fold for atovaquone.
Homogeneity of the RI of the different drugs was evaluated for
all the selected lines. The results were homogeneous for 4 of the 5
selected lines. For these 4 lines, there was no statistical difference
between the IC50 values (concentration of drug that inhibited 50%
of parasite growth) for all the tested lysosomotropic drugs.
Nevertheless, the drug selection protocol led, after a 4-year drug
pressure, to the expression of different phenotypes in term of IC50
values for the line Y-ART2 (Figure 1). The Y-ART2 line has
acquired a notably higher resistance to endoperoxide and
especially to ART (resistance index up to 260) and its derivatives
artesunate and artemether (Table 2), and has also acquired an
unexpected in vitro resistance to atovaquone (RI=2.2) (Table 3).
Because of its divergent phenotype, this line was not included in
the determination of the resistance phenomenon presumed to be
common to the 4 other lines and will be discussed later in detail.
Excluding Y-ART2, the IC50 values for quinolines and for the
endoperoxides of the 4 resistant lines were statistically higher than
those of the Y-control line (p,0.05). For SP and atovaquone, no
statistical difference was found between the IC50 values from the 4
resistant selected lines and the IC50 values from the control line.
(SP p=0.56, ATQ p=0.15).
These homogeneous values pointed to a common factor in the
acquisition of resistance to quinolines and endoperoxides in all
these resistant-lines.
Figure 1. Experimental scheme of the 5-year drug resistance selection protocol.
doi:10.1371/journal.pone.0032620.g001
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was restricted to lysosomotropic antimalarial drugs. A common
mode of resistance, possibly localized in the food vacuole, could
explain the behavior pattern shared by all these lysosomotropic
drugs, whatever the molecule used to select the resistance.
After 5 years of continuous drug pressure, certain selected lines
(experiments performed only for lines Y-ART3 andY-CQ1
randomly chosen) were maintained in vivo but without any drugs
(release of drug pressure) over 20 passages. The resistance to
lysosomotropes (quinolines and artemisinins) of these released lines
was totally lost with IC50 values statistically not different from
those of the Y-control line (p.0.05), whereas the sensitivity to SP
remained unchanged (Tables 1, 2, 3). These data indicated that
the resistance acquired in these conditions was unstable and easily
lost in the absence of drug pressure, possibly by restoration to a Y-
control-like phenotype, meaning there was a high biological cost
for these drug-resistance parasite phenotypes.
P. yoelii nigeriensis is a virulent parasite able to kill mice within 5–8
days with a peak of parasitemia of 50–70% when using an
inoculum of 1610
8 infected red blood cells. With the same
inoculum, infections with selected parasites from groups Y-ART,
Y-CQ did not kill mice and the levels of parasitemia were lower.
Moreover, mice infected with these selected lines that are much
less virulent were able to overcome the infection and cure
themselves (Figure 2A). These results demonstrated that the
acquisition of resistance certainly linked to a high fitness cost led to
a loss of virulence of the parasite. Additionally, the release of drug
pressure resulted in an enhancement of parasite virulence for each
line (Figure 2B). These data exposed the relationship between
virulence and resistance [6]. In summary, a homogeneous
phenotype of multi-drug resistance was found after drug selection
with ART and CQ for 4 out of 5 lines. This resistance was
pleiotropic but restricted to lysosomotropic drugs.
Resistance to lysosomotropic drugs was not associated
to known resistance markers
Multidrug resistance in Plasmodium is mainly associated to
modifications of genes coding for proteins such as PfMDR1
orthologues [7][8]. In rodent malaria models, amplification of
the mdr1 gene has been linked to CQ, ART and MQ resistance
[9][10]. However, comparative studies between our resistant
lines and the control showed neither variations in the copy
number of pymdr1 (PY00245, an orthologue of pfmdr1)n o r
coding sequence differences that might explain the resistance.
Moreover, mRNA quantification revealed statistically lowered
transcriptional levels of pymdr linked with the acquisition of
resistance (p=0.002) (Figure 3A). This result might be mediated
by transcriptional regulators. This low transcription could be
linked to the ATP cost of ABC transporters such as pymdr1 and
the need for resistant parasites to limit useless energy
consumption.
As a confirmation, penfluridol, a potent mdr1 inhibitor [11], did
not reverse the resistance to mefloquine (neither CQ or
ARTresistance; data not shown), whereas this inhibitor had been
shown to reverse resistance in mefloquine-resistant lines of P. yoelii
and P. falciparum [12][11]. These data confirmed that the gene
mdr1 was not involved in our P. yoelii model of multi-drug
resistance.
Table 1. Ex vivo chemosusceptibility values for quinolines.
Lines CHLOROQUINE MEFLOQUINE QUININE
pressure release pressure release pressure release
IC50 RI IC50 RI IC50 RI IC50 RI IC50 RI IC50 RI
Y-control 0.1160.014 1 - - 0.160.03 1 - - 1.0260.3 1 - -
Y-ART1 1263.3
* 109 nd - 10.361.7
* 103 nd - 17.662.5
* 17 nd -
Y-ART2 16.664.8
* 150 nd - 7.662.3
* 76 nd - nd - nd -
Y-ART3 9.561.8
* 86 0.0960.02 0.8 11.162.6
* 111 0.0360.004 0.3 24.365.5
* 24 0.3660.03 0.35
Y-CQ1 1462.4
* 127 0.07360.03 0.66 1262.9
* 120 0.02560.002 0.25 39611
* 39 0.5160.05 0.5
Y-CQ2 16.861.8
* 152 nd - 7.463.3
* 74 nd - 27.7617
* 27 nd -
doi:10.1371/journal.pone.0032620.t001
Table 2. Ex vivo chemosusceptibility values for endoperoxides.
Lines ARTEMISININ ARTESUNATE ARTEMETHER ARTEMISONE
pressure release pressure release pressure pressure
IC50 RI IC50 RI IC50 RI IC50 RI IC50 RI IC50 (nM) RI
Y-control 0.1760.04
Y 1 - - 0.0460.002 1 - - 0.0360.006 1 0.0260.002 1
Y-ART1 1.860.84
*Y 11 nd - 0.4360.04
* 11 nd - 0.660.075* 18 0.3760.025* 19
Y-ART2 45611.3
* 264 nd - 3.4762.06
* 87 nd - 1.660.53* 53 0.5760.12
# 29
Y-ART3 0.860.11
*Y 5 0.06 6 0.009 0.4 0.3860.01
* 10 0.0260.003 0.3 0.460.06* 14 0.2860.04* 14
Y-CQ1 1.3660.03
*Y 8 0.05 6 0 0.3 0.5160.23
* 13 0.0260.003 0.3 0.660.008* 18 0.4260.025* 21
Y-CQ2 0.960.2
*Y 5 nd - 0.4060.10
*Y 10 nd - 0.560.033* 15 0.3160.037* 16
doi:10.1371/journal.pone.0032620.t002
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resistance index to CQ (Table 1). In P. falciparum, resistance to CQ
has been linked to mutations in the gene coding for the PfCRT
channel, the chloroquine resistance transporter [13][14]. Howev-
er, no single-nucleotide polymorphism (SNP) was found here on
the P. yoelii orthologue cg10 of our selected lines (data not shown).
Moreover, verapamil which reverts CRT-mediated CQ resistance
[15], did not have any effects on CQ sensitivity in our resistant
lines (data not shown). Additionally, chlorpromazine which is
known to potently chemosensitize CQ resistant strains of P.
falciparum to CQ [16], did not affect the CQ sensitivity of our
resistant murine malaria models (data not shown) as observed by
others [17].
Resistance of the selected lines to ART and to its derivatives was
observed. ART resistance has been correlated to an increased
mRNA transcription and thus increased expression of the protein
TCTP (Translationally Controlled Tumor Protein), an identified
target of artemisinin [18]. However, neither significant difference
in mRNA expression nor SNP were detected in the present case in
the Y-ART lines (data not shown), strongly suggesting a different
resistance mechanism. These results obtained with a murine
model should not be considered as directly transposable to the
understanding of the resistance of the human malaria parasite, P.
falciparum, but as a contribution on drug-resistance of malaria
strains.
In summary, all these data suggested that these resistant lines
circumvented the effects of lysosomotropic drugs by a global
mechanism of resistance but without implicating the already
known resistance factors. As a marked resistance to quinolines was
ubiquitously observed in these selected lines, and as these drugs are
known to act by interfering with hemoglobin catabolism, our
investigations then focused on possible alterations in heme
metabolism.
Acquisition of lysosomotropic drug resistance was linked
to impaired hemozoin production
Microscopically, lower hemozoin (Hz) concentrations were
observed in the resistant parasites than in the Y-control. This
finding was confirmed by the impossibility to concentrate late
parasite forms from the selected lines with magnetic columns [19]
contrary to the Y-control line, since this methodology acts trough
the Hz paramagnetic properties.
The study of malaria pigment showed a significant reduction in
the Hz content in the resistant lines compared with the control line
(Table 4 & Figure 4). After the release of drug pressure and
concomitant with the loss of resistance, the Hz content
significantly increased, reaching values statistically not different
from those of the Y-control line (p.0.05) (Table 4). A statistically
significant inverse correlation was found between the Hz content
and resistance to lysosomotropes (p,0.05 and ART r=20.82,
ATS r=20.88, artemisone r=21.00, artemether r=20.98, Q
r=20.79, CQ r=20.75, MQ r=20.75). No correlation was
found for not lysosomotrope drugs (SP : p=0.23, r=0.7 and
ATQ: p=0.233, r=0.15) (Figure 5). These results clearly
demonstrated the implication of the Hz synthesis pathway in the
mode of action of the lysosomotropic drugs endoperoxide and
quinoline.
Hz formation was a common target for quinolines and
endoperoxides and the disappearance of Hz would lead to a
pleiotropic resistance phenotype as observed here. That may
explain why the same phenotype was obtained between the lines
resulting from the CQ or ART selection protocol. As expected,
drugs known not to interfere with Hz-mediated heme catabolism
such as SP and atovaquone did not show any reduced activity
against the resistant lines. Since the decreased hemozoin
concentration was the common parameter in all the resistant lines
studied.
Table 3. Ex vivo chemosusceptibility values for not-
lysosomotropes.
Lines SULFADOXINE-PYRIMETHAMINE ATOVAQUONE
pressure release pressure
IC50{ RI IC50{ RI IC50 (nM) RI
Y-control 6.561.16 1 nd - 32.265.7 1
Y-ART1 4.50
# 0.7 nd - 23.9614.3* 0.7
Y-ART2 5.160.73 0.8 nd - 70.1619 2.2
Y-ART3 5.961.23 0.9 5.560.74 0.84 23.664.9* 0.7
Y-CQ1 5.060.9 0.8 4.560.13 0.7 18.663.2* 0.6
Y-CQ2 5.0
??? 0.8 nd - 20.569.5* 0.6
doi:10.1371/journal.pone.0032620.t003
Figure 2. Parasitemia (%) profile of Y-control line, selected
resistant lines and release lines (inoculum 1610
8 parasites).
Drug resistance selection led to a loss of fitness and virulence as all the
selected lines became not-lethal (A). Release of drug pressure partially
restores fitness and virulence; lines could become lethal again (B).
Parasitemia kinetic of the strains Y-ART3 (large square), Y-CQ2 (small
square), Y-control (circle) and death of mice (cross) are shown. Figure 2
is one representative experiment from more than 5 experiments done
with each of the strains tested.
doi:10.1371/journal.pone.0032620.g002
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which indicate that potent artemisinin activity is dependent on
hemoglobin digestion by the parasite with heme as target for
endoperoxides [20]. However, hemoglobin digestion is crucial to
parasite for amino-acids provision and such level of Hz decreased
would indicate a quasi-arrest of hemoglobin degradation. Others
demonstrated that hemoglobin digestion rate was not altered in a
chloroquine- resistant P. berghei model, even if the heme rate was
decreased in this murine malaria resistant strain in comparison
with the sensitive one [21]. Decreased heme content as well as a
decreased of Hz production observed add arguments to another
pathway of heme degradation [21,22].
We hypothesized that there was an alternative pathway involved
in heme detoxification other than Hz formation. Therefore
possible modifications in heme catabolism pathways were
investigated.
Resistant lines showed an alternative heme catabolism
pathway
In malaria parasites, the majority of the toxic heme, resulting
from hemoglobin digestion, is eliminated by crystallization to Hz.
Recently, the protein HDP (Heme Detoxification Protein) was
found to potently catalyze this biocrystallization process [23].
Among heme detoxification protagonist such as HRP2 (Histidine
Rich Protein 2) and lipids, the HDP mediated one, has been
described as being the most efficient and is ubiquitous to all
Plasmodium species. Furthemore, P. yoelii HDP (PyHDP) was found
to be as active as P. falciparum HDP in terms of Hz crystallization
[23].
As pyhdp is still not annotated in available databases (PlasmoDB,
GeneBank), a partial sequencing of pyhdp was therefore carried out
(Figure 6). No SNP were found to explain the lowered
concentration of Hz in the selected lines. Nevertheless, mRNA
quantification revealed that HDP was statistically under expressed
in resistant lines compared with the Y-control line (p=0.017)
(Figure 3B) whereas the gene coding for HDP protein couldn’t be
deleted in Plasmodium highlighting the crucial presence of that gene
for parasite viability [23]. This last finding corroborated the results
obtained for the Hz concentrations in the resistant lines, thus
Figure 3. mRNA expression of pymdr (A) pyhdp (B) and pygcs (C). The results show relative expression in arbitrary units normalized to pysts
expression (mean 6 SEM of 3 independent experiments). *Comparison of Y-ART2, Y-ART3 and Y-CQ2 vs Y-control: p,0.03 by a one-way analysis of
variance test and then p,0.05 by a pair-wise multiple comparison test vs Y-control group (Dunnett’s method).
doi:10.1371/journal.pone.0032620.g003
Figure 4. Epifluorescence microscopy. Y-ART3 line schizont stained
with acridine orange (a) showed a typical multiple nuclei stage but no
malaria pigment inclusion could be observed in a bright field (a’). Y-
control line schizont stained with acridine orange (b) showed also a
typical multiple nuclei stage but there is a large amount of malaria
pigment also called hemozoin (the black inclusion) observed in a bright
field (b’).
doi:10.1371/journal.pone.0032620.g004
Table 4. Hemozoin concentrations in Y-control and selected
lines.
Lines Hemozoin concentration
pressure release
Y-control 21.0863.82 -
Y-ART1 0.3460.09* nd
Y-ART2 0.4060.24* nd
Y-ART3 0.5160.19* 1963
Y-CQ1 0.3260.08* 1761
Y-CQ2 0.3960.17* nd
doi:10.1371/journal.pone.0032620.t004
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tropic drug multi-resistance (Figure 7). This lower expression could
be explained by the useless transcription of that gene upon the
possible diminution of the Hz synthesis pathway. And thus the
decrease in the Hz-based heme degradation pathway suggested
the existence of a substitute pathway necessary to eliminate the
toxic free heme (Figure 7). As a plausible alternative pathway was
via glutathione-mediated heme detoxification [24], a comparison
of the reduced glutathione (GSH) concentrations in the resistant
lines versus the Y-control was carried out. The results showed that
the concentrations of GSH were statistically higher in the resistant
lines tested (p=0.002) (Table 5). As expected, the GSH
concentrations fell dramatically after the release of drug pressure
to reach the level observed in the Y-control line (Table 5).
To validate this finding, chemosusceptibility to methylene blue
(MB) was assessed on resistant and control lines. Methylene blue
inhibits glutathione reductase and thus impedes the recycling of
glutathione disulfide (GSSG) to reform GSH [25]: this depletion of
GSH is the basis of its antiplasmodial mode of action.
The in vitro chemosensitivity assay to MB showed a statistically
decreased effect of this compound on the resistant lines (p,0.003).
This in vitro resistance to MB was lost after release of drug pressure,
which reinforced the results of the GSH measurement (Table 6). A
possible explanation could be that the increased concentration of
GSH in resistant lines renders the GSH depletion effect of MB
(and thus its antimalarial activity) less marked.
We can suppose that the combination results published by
others could be due to inhibition of GR on whole cycle
(explaining the synergistic effects with ART) whereas inhibition
of HZ pathway is occurred only on mature forms (explaining the
antagonistic effects with some quinolines). Indeed, we have
previously demonstrated the different moments of action on the
erythrocytic malaria cycle of CQ and ART [26] that act from
the mature trophozoite and since ring forms, respectively.
However, on the present work, no combination was tested, we
cannot thus speculate about the MB activity according to the
partner drug and conclude about the ambiguous results obtained
by others.
From this it may be deduced that there is a modification of
the parasite GSH metabolic pathway in the resistant lines. The
GSH level is known to be increased by over-expression of the
limiting enzyme c-glutamyl-cysteine-synthetase (cgcs) [27].
Surprisingly, we demonstratedt h a tt h et r a n s c r i p t i o no fcgcs
was statistically lower in resistant selected lines (p,0.05)
(Figure 3C). This surprising result could be related to a negative
feedback existing between cgcs and heightened GSH concen-
tration. . Considering the essential role of GSH for parasite
development it might be possible that the present resistant lines
used an alternative pathway to provide GSH. In a previous
study, the provision of GSH via the host cells has been proposed
[22].
In summary, different multidrug-resistant lines of P. yoelii were
obtained. Whatever the molecules used for the selection pressures,
the same alterations in chemosusceptibility were observed. This
drug resistance phenotype seemed to be linked both to the
metabolism of heme and of GSH.
Figure 5. Correlation between IC50 values for CQ, ART, artesunate and SP in selected and control lines. The line for Y-ART2 was not
included. IC50 values (mean of at least 3 independent experiments) are expressed in mM for CQ, ART, artesunate and as dilution (610
6) of SP stock
solution (200 mg sulfadoxine+10 mg pirymethamine/mL). The Hz content is expressed as the log of concentration (pmoles of FPPIX/1610
6
trophozoites). A statistically significant negative correlation was found between the Hz content and the IC50 values for CQ (p=0.03; r=20.75) ART
(p=0.01; r=20.82) and artesunate (p,0.001 r=20.88) while there was no statistically significant correlation with the IC50 value for SP (p=0.23,
r=0.7). *calculated by Spearman’s rank-order correlation test.
doi:10.1371/journal.pone.0032620.g005
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The mode of action of ART and related compounds has been
widely debated [28][29]. Some studies indicated that the action of
ART was mediated by heme-activation which generates toxic
alkylating radicals after the opening of the endoperoxide bridge
[30], and by inhibition of Hz production. ART could thus act by
alkylating heme [31], some proteins [32] or by inhibiting Hz
formation with adducts of ART-heme [33][34,35]. Other authors
have suggested that heme was not a prerequisite for ART activity
and suggested a not-heme mediated activation [36].
Figure 6. Alignment of predicted HDP sequence from the Y-control line cDNA sequence (P. yoelii) with P. berghei and P. falciparum
referenced sequences (genes pb000650.00.0 and pf14_0446 respectively). The alignment was performed with ClustalW2 and treatment of the
data with BoxShade 3.21; black and grey boxes indicate respectively identical and similar amino-acids between the 3 sequences studied. The Y-
control sequence shares 97% identity with the P. berghei sequence and 77% with the P. falciparum sequence (data from ClustalW2).
doi:10.1371/journal.pone.0032620.g006
Figure 7. Scheme of Heme catabolim pathways in Plasmodium. Pathway A: GSH mediated heme catabolism. Pathway B: hemozoin
biocrystallisation heme mediated catabolism. The pathway B is the standard way of heme catobolism, in majority present in sensitive and revertant
lines instead of way A should be predominant in the resistance selected lines presented here. CYT : cytoplasm; FV: food vacuole; RBC: red blood cell.
doi:10.1371/journal.pone.0032620.g007
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opinions could both be plausible if considered together. The
quinolines are exclusively dependant on Hz production to be toxic
and the resistance indices found in the present study for these
drugs gave the highest values. On the contrary, the resistance
indices of endoperoxides were more moderated. The divergence in
resistance to these two different classes of drugs could be due to the
mode of action of artemisinin-based drugs that involves multiple
parasitic targets. Such a hypothesis was reinforced by the data
obtained with the strain highly ART-resistant Y-ART2 (Table 2).
This line showed a similar pattern of Hz concentrations as the two
other ART-selected lines (Table 4). On the contrary, the
chemosusceptibility data indicated that this line had very high
resistance to ART which was statistically higher than the other
selected lines (p,0.001) (the ART resistance index was about 260-
fold compared with the control line). Additionally, the resistance of
this Y-ART2 line was considerably increased for all the ART
derivatives but the resistance to quinolines was not significantly
increased (Table 1). Surprisingly, the sensitivity to atovaquone, a
mitochondrial acting antiplasmodial drug, was statistically lowered
in this line (RI of 2.2-fold) (p,0.05) while the sensitivity to SP was
unchanged (Table 3). Previous studies have evoked the role of
mitochondria in ART activity [37]. The unexpected correlation
found between high resistance to ART and decreased atovaquone
sensitivity could be explained by modifications in certain
mitochondrial targets such as NADH oxidase or electron transport
chain [38]. These latter data showed that this Y-ART2 line could
have acquired a possible additional resistance pathway to ART
different from the Hz-mediated resistance. However extended
studies on this line remains necessary to elucidate the molecular
mechanisms that drive this upper resistance to artemisinin.
In summary, resistance to ART and thus its mode of action
seems to be not only linked to heme metabolism and further
investigations are necessary to determine how this Y-ART2 line
was able to resist such high concentrations of artemisininins.
Interestingly, artemisinin derivatives and synthetic endoperox-
ydes are also active against Schistosoma sp [39,40,41]. This parasite
from the trematodeclassisobviouslyverydifferenttoPlasmodiumbut
both parasites are able to produce hemozoin as a hemoglobin
catabolism product. Quinolines, known to be dependant of the
hemozoin pathway, were active on schistosoma as well [42][43]. On
the other way, artemisinins are weakly active (100 to 1000-fold less)
against Babesia sp, a haematozoar close to Plasmodium, but which
does not produce hemozoin trough its metabolism of hemoglobin
[44]. Nevertheless, a weak activity of artemisinins exists on Babesia
sp, probably arguing in favor of additional mechanism of action of
these molecules beyond the heme catabolism. This hemozoin-
independent activity, can also explain why the P. yoelii selected
resistant lines here described are not totally resistant to artemisinins
(same range as Babesia sp.) despite a quasi absence of hemozoin
production. Finally, the ‘‘over-resistance’’ of the line Y-ART2 could
be explained by such dichotomy of the mode of action of
artemisinins and consequently, through the setup of additional
mechanism(s) of resistance in this line. Furthermore, these data are
supplementary arguments to plaid to the pivotal involvement of
hemozoin metabolism pathway in the artemisinins activity but also
to its not-exclusive contribution.
Conclusion
In the present study, P. yoelii parasites that were multi-resistant
to lysosomotropic drugs were selected. We demonstrated that this
resistance is linked to major modifications in the parasites’ heme
metabolism. Even if this murine model certainly did not mimic
resistance phenotype and resistance mechanism of human P.
falciparum to tested drugs, it has permitted to provide new
mechanistic elements of the artemisinin mode of action on a
murine malaria parasite. Thus, we confirmed that quinolines act
against Plasmodium via Hz production inhibition, but also that there
is a link between the antiplasmodial action of endoperoxides and
heme metabolism. However, we also suggested that endoperoxide
activity is not only dependant on heme metabolism but can also
act on other targets that could be mitochondria and certainly other
targets. For field applications, this study also indicates that future
treatment, currently in clinical trials [45,46] combining an
artemisinin derivative and a drug that interacts with alternative
heme catabolism pathways (such as by reducing GSH content)
could greatly enhance antiplasmodial activity and circumvent
ART resistance. Such considerations appear crucial in the current
context of early artemisinin resistance in Asia.
Materials and Methods
Parasites, mice and drugs
Swiss female mice (Janvier, France), 6–8 weeks old, were used to
maintain parasites and select resistant lines. The Plasmodium yoelii
nigeriensis strain was kindly provided by Dr. Irene Landau
(Museum d’Histoire Naturelle, Paris, France). Chloroquine
diphosphate (CQ), artemisinin (ART), mefloquine, quinine
hydrochloride, verapamil, chlorpromazine and penfluridol were
purchased from Sigma-Aldrich. Sulfadoxine-pyrimethamine
(200 mg sulfadoxine plus 10 mg pyrimethamine per mL: Fansi-
darH) was purchased from Roche, France. Atovaquone and
artemether were kindly provided respectively by Glaxo-Smith-
Kline and Rhone-Poulenc. Artemisone wassynthesized according
to previously published protocols [47][48].
Selection of drug resistant strains
Selections were carried out by submitting parasites to
progressively increased doses of ART or CQ according to Peters
Table 5. GSH concentrations in selected, released and control
lines.
Lines GSH (nmoles/1610
9 parasites ± SEM)
pressure release
Y-control 31.564-
Y-ART2 136.5613* nd
Y-ART3 143.5613* 26 6 6
Y-CQ1 124633* 22
#
doi:10.1371/journal.pone.0032620.t005
Table 6. In vitro chemosusceptibility of lines Y-ART3, Y-CQ1
and Y-control to methylene blue (MB).
Lines MB IC50 (ng/mL ± SEM){
pressure release
Y-control 16.563.4 -
Y-ART3 8506414* 9.966.4
Y-CQ1 1606208* 12.468.3
doi:10.1371/journal.pone.0032620.t006
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Female Swiss albino mice were infected intraperitoneally with
1610
6 infected red blood cells (IRBC). One hour later, drug was
administered subcutaneously (s.c.) to animals. Follow-up of
parasitaemia was daily monitored by caudal blood collection
and giemsa-stained thin blood smears were read microscopically
by at least two independent readers. When the parasitemia
reached values ranging from 2 to 5%, blood was collected and
injected into new mice and then drug pressure was reapplied
corresponding to one passage. Selections of drug resistant parasites
were performed over a period of five (5) years corresponding to
about 340 passages for the selected lines and about 760 passages
without any drug for the Y-control line. For artemisinin three mice
were infected and treated and 2 mice were used for CQ. Two
groups of selected lines corresponding to the drug CQ and ART
used were then subdivided, studied in parallel and named Y-ART
[1,2,3] and Y-CQ [1,2] respectively (Figure 1).
The doses of the drugs ranged from 25 mg/kg to 185 mg/kg for
CQ (vehicle: normal saline), 20 mg/kg to 120 mg/kg for ART
(vehicle: DMSO) (vehicle: normal saline with 15% DMSO). The
phenotype of resistance of these 5 selected lines (+ the control line)
was firstly assessed after 3 years of drug pressure (by the Fink’s test
and the ex vivo test). Then the evolution of the phenotypes was
monitored only with the ex vivo test. At the end of the 4
th year of
drug pressures, phenotypic divergences appeared but remained
stable during all over the 5
th year of the experiment. To explore
stability or reversion of resistance, 5-year old selected strains were
maintained in mice (as previously described) but without drug
treatments for at least 20 passages.
Evaluation of in vivo chemosusceptibility
The Fink’s test was used to determine the effect of drugs in vivo
[4]. Mice were infected with 1610
7 infected red blood cells (IRBC)
from the selected or the control lines after 3-year old selected
strains and treated with unique drug doses (ART 120 mg/kg, CQ
185 mg/kg; the controls were obtained by treating infected mice
with only drug vehicle (DMSO, normal saline or normal saline
with DMSO 15%). Parasitemia was monitored until 1 month after
infection.
Ex vivo chemosusceptibility assay
Heparinized 6–10% parasitemia infected blood was collected by
retro-orbital puncture and was twice washed with RPMI. The red
blood cell (RBC) pellets were resuspended in RPMI supplemented
with 25% FCS and 0.5 mg/mL hypoxanthine and distributed in
96-well microplates prefilled with 100 mL of drug/well for a final
volume of 200 mL and a final hematocrit of 2%. Immediately,
3[H] (0.05 mCi final) was added and the plates incubated at 37Cu,
5% CO2 for 24 hours. The plates were then submitted to freeze-
thaw cycles to lyse the cells and nucleic acids were collected on
fiberglass filters. Tritium incorporation was measured with a
microbeta counter (Perkin-Elmer).
To investigate the effect of chemosensitizers, parasites were co-
incubated following the methodology used to determine ex vivo
sensitivity (ART, CQ and mefloquine) with chemosensitizing
agents (verapamil, penfluridol, and chlorpromazine purchased
from Sigma-Aldrich) at concentrations corresponding to their
IC20–30.
Animal procedures
All procedures involving living animals were carried out in the
animal facilities of the Parasitology Department of the Toulouse
(France) University Hospital under the control of the National
Veterinary Services and performed according to European
regulations (EEC directive 86/609 dated 24 November 1986).
The staff in charge of the animal experiments had received the
appropriate training. All in vivo studies were approved by the
French Institutional Animal Experimentation Ethic Committee
(approvals MP/R/05/32/11/07 and MP/04/04/01/08 for the
selection of drug resistant clones and the Fink’s test, respectively).
Determination of gene copy number
Genomic DNA was extracted from infected RBC (IRBC) with a
High Pure PCR template preparation kit (Roche), in accordance
with the manufacturer’s instructions. The RT-PCR reaction was
performed on a LightCycler V1.5 (Roche) in a 10 mL final
reaction mixture with 2.5 mL DNA template, 0.5 mM primers
(Eurogenetc, Belgium) (TUB1/2 and MDR1/2 (Table S1)), 4 mM
MgCl2 and 1 mL Fast Start SYBR green (Roche). The gene
amplification copy was estimated by comparison with the Cp value
of b-tubulin (1 copy reference gene) and the Ct value of pymdr
(target gene) between the sensitive control strain and the resistant
strains through the 2
2DDCt method [50]. Each reaction was
performed in triplicate and the experiment repeated three times.
Primers were designed using PRIMER3 software and the
PLASMODB database.
mRNA extraction and quantification
Parasites were synchronized with a percoll gradient to extract
mRNA from homogeneous stages. Nine parts of percoll (Sigma)
were mixed with one of 10X HBSS without Na2HCO3 (Sigma)
and adjusted to pH 7 with 0.3 M hydrochloric acid. A
discontinuous gradient was obtained by successive layering of
decreasing concentrations of the percoll solution (80, 75, 72, 68,
60, 45 and 20%). Heparinized whole blood was then gently
deposited on the gradient and it was centrifuged 15 min/1,900 g.
Parasites were isolated according to their cycle age with older
forms in the two first blood layers and younger forms in the third
and fourth layers. The selected blood layers (late trophozoites and
young schizonts) were collected and washed twice in cold
Phosphate Buffer Saline (PBS). Blood pellets were then mixed
with 800 mL of Trizol (Invitrogen) and stored at 280uC until RNA
extraction. Total RNA was extracted by adding 200 mLo f
chloroform and spinning at 4uC 18,000 g/30 min. The superna-
tants were mixed with an equal volume of 70% ethanol and placed
on an RNeasy MiniElute Cleanup column (Quiagen). The last
part of the RNA extraction was performed in accordance with the
supplier’s protocol. RNA samples were stored at 280uC until
reverse transcription. Before carrying out RT, gDNA was
eliminated from the RNA by RQ1 DNase I treatment (Promega).
The absence of gDNA contamination was assessed by performing
a b-tubulin RT-PCR reaction on DNase treated RNA.
Reverse transcription was carried out on 1 mg RNA with a
Reverse Transcription System kit (Promega). Quantification was
done by RT-PCR using the previously described protocol to
estimate the pymdr copy number. The gene PY03295 (seryl-tRNA-
synthetase) was used as a housekeeping gene. All primer couples
(Eurogenetec, Belgium) (Table S1) were tested with serial log
dilutions of cDNA to ensure the high efficiency of the reactions
(above 95%). Primers were designed using PRIMER3 software
and the PLASMODB database (www.plasmodb.org).
Hemozoin extraction and quantification
Hemozoin extraction and assay were done following the
protocol of Orjih et al [51] with modifications. In order to
normalize our results for the absolute number of parasites, for each
sample the parasitemia was microscopically determined by at least
2 independent readers, the RBC numeration was also determined
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lysed with PBS plus 0.08% saponin. Each pellet was then re-
suspended in SDS solution (2.5% SDS in Tris-HCl 25 mM) and
incubated overnight. The extracts were then centrifuged (1 h/
18,000 g) and the Hz pellets harvested and washed with SDS
solution. Hz decrystallisation was achieved by treatment for 2 h at
room temperature with SDS solution plus 0.1 M NaOH and the
Hz quantified by reading the absorbance at 405 nm. A reference
curve was obtained with dilutions of FPIX chloride solution
incubated in NaOH-SDS solution. The residual hemin/hemoglo-
bin background level was estimated by treating the blood of
healthy mice with the same protocol.
Measurement of reduced GSH
Whole blood of infected mice (6 to 15% parasitemia) was
collected (with heparin), diluted (1/3 v/v) with cold PBS and
applied to a leukocyte removal disposable column (10 mL syringe
filled with 100 mg of microcrystalline cellulose 20 mm (Sigma)).
IRBC lysis was obtained by incubating 5 min on ice in 10 mL cold
PBS containing 0.025% saponin. Parasites were washed twice with
cold PBS and homogenized in three volumes of cold 5%
sulfosalicylic acid. The suspension was submitted to three
freeze/thaw cycles using liquid nitrogen and a 37uC water bath
and spun at 4uC (10 min/18,000 g). 50 mL of supernatant was
mixed with 150 mL of Tris-HCl/EDTA buffer pH 9 plus 10% of
5,59-dithiobis nitrobenzene solution in DMSO. The absorbance
(maximal peak at 412 nm) was determined at 405 nm using a
10 nm band pass. A reference curve was obtained by measuring
the absorbance of serial GSH (Sigma) dilutions in 5% SSA.
Epifluorescence microscopy
Infected blood from Y-control and Y-ART was collected
(100 mL) with heparin and then washed with 1 mL PBS. 20 mL
RBC were re-suspended in 1 mL acridine orange (Merck) solution
(5 mg/mL in PBS) and incubated 5 min at room temperature. The
blood was then washed 3-times with 1 mL PBS and smeared on a
glass slide. Slides were observed immediately after preparation,
with a Leica DPMI fluorescence microscope at the appropriate
excitation wavelength (480 nm).
Statistical Methods
To interpret and analyze the results, a logarithmic transforma-
tion was carried out to convert some not-Gaussian data to a
normal distribution. Results were given as mean +/2 SEM. To
compare groups, a one-way or a Kruskal-Wallis one way analysis
of variance tests were performed as appropriate and if a difference
was found between groups, then a multiple comparison procedure
(Dunnett’s or Dunn’s method) was done. The relationships
between two variables were analyzed by Spearman’s rank-order
correlation test. A comparison was considered statistically
significant if the p value was #0.05. All tests were performed
using the SigmaStat (2.03) statistical program (SigmaStat, Heame
Scientific Software, Chicago, USA).
Supporting Information
Table S1 Primers used for the RT-PCR and sequencing
experiments. NA=not annotated.
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